Skip to main content

Kanglin Biotechnology (Hangzhou) Co., Ltd.

Tuesday, February 27, 2024
Gene/Cell Therapy
Kanglin Biotechnology (Hangzhou) Co., Ltd. was founded in 2015 with the goal of translating advances in genetic science into curative treatments for previously incurable diseases. We believe in the groundbreaking potential of genetic medicine and have set ourselves the goal of developing first-in-class and best-in-class gene therapies. Guided by scientific innovation, our aspiration is very simple, to make good medicine for patients.  We are currently developing gene therapies for devastating diseases such as β-thalassemia, Parkinson’s disease, HIV, hemophilia and others. Years of dedicated research and development have yielded initial results. Investigator-initiated trials of our β-thalassemia candidate has shown promising results with best-in-class potential in efficacy and safety in addition to dramatically reduced manufacturing costs, e.g., COGs is roughly lower than that of competitive products by 10x.
Youren Tong, Head of R&D - Kanglin Biotechnology (Hangzhou) Co., Ltd.




CEO/Top Company Official

Dr. Haoquan Wu

Lead Product in Development

Lentiviral based β-thalassemia gene therapy

Development Phase of Primary Product

Phase I

Number Of Unlicensed Products

3 ( β-thalassemia, HIV functional cure, Parkinson's disease)

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.